2nd Edition of Cell & Gene Therapy World Conference(CGTWC) 2026

Scientific Sessions

Regulatory and Quality Control in CGT Manufacturing: Harmonisation and Compliance

Robust regulatory oversight and stringent quality control are fundamental to assuring the integrity and safety of cell and gene therapy (CGT) manufacturing. As the sector expands internationally, harmonisation and compliance with different regulatory approaches have been prioritised. Creating clear and consistent frameworks enhances product safety and advances global access to innovative therapies.

Related Sessions

CRISPR Cas9 and Beyond: Emerging Genome Editing Platforms
Precision Genome Editing: From Target Discovery to Clinical Application
Engineering the Immune System: Gene and Cell Based Modulation
Non Viral Gene Delivery Strategies: Safety, Scalability, and Translation
Stem Cell Derived Therapeutics: iPSCs, Organoids and Tissue Engineering
Allogeneic vs Autologous Cell Therapies: Manufacturing, Efficacy, and Access
Manufacturing for Personalized Medicine: Customised Cell Products at Scale
Analytics, Potency Assays, and Rapid Release Strategies
CGTs for Monogenic Disorders: Delivering the Cure
Gene and Cell Therapies in Oncology: CAR T, NK, TCR, Oncolytic Approaches
Neurological and Neurodegenerative Disease Applications of CGTs
Market Access, Health Economics, and Reimbursement in CGT
Global Access and Equity: Bridging the CGT Innovation Gap
The Future Landscape of Cell and Gene Therapies: 2030 and Beyond
Cell and Gene Therapy Clinical Development
Cell and Gene Therapy Pipeline Analysis